Investigation of NF-κB-94ins/del ATTG and CARD8 (rs2043211) Gene Polymorphism in Acute Lymphoblastic Leukemia

Chen Zhang1, Fengjiao Han1, Jie Yu1, Xiang Hu1, Mingqiang Hua1, Chaoqin Zhong1, Ruqing Wang1, Xueyun Zhao1, Yufeng Shi2, Chunyan Ji1,3 and Daoxin Ma1*

1Department of Hematology, Qilu Hospital of Shandong University, Jinan, China, 2Institute for Financial Studies and School of Mathematics, Shandong University, Jinan, China, 3Shandong Provincial Key Laboratory of Immunohematology, Qilu Hospital of Shandong University, Jinan, China

NLRP3 inflammasome has been widely implicated in the development and progression of various hematological diseases. However, how NLRP3 inflammasome contributes to the pathogenesis and clinical features of acute lymphoblastic leukemia (ALL) is still unknown. Here, in ALL patients’ bone marrow, we investigated the single-nucleotide polymorphisms (SNPs) and expression of NLRP3 inflammasome related genes, NF-κB, NLRP3, IL-1β, IL-18, Caspase-1, and ASC. A total of 308 ALL patients and 300 healthy participants were included in this study. D allele and DD genotype under codominant model of NF-κB-94ins/del ATTG were showed as a protective factor in susceptibility of ALL. As for CARD8 (rs2043211), AT/TT genotype under dominant model and TT genotype under codominant model greatly increased the ALL susceptibility. We further studied the relationship between NLRP3 inflammasome genetic polymorphisms and clinical relevance. The results showed that DD genotype of NF-κB-94 ins/del ATTG and AT/TT genotype of CARD8 (rs2043211) contributed to lower WBC count and T-cell immunophenotype, respectively. Moreover, we also found that AT and TT genotypes of CARD8 (rs2043211), GT and TT genotypes of IL-1β (rs16944), and TT genotype of IL-18 (rs1946518) were associated with higher mRNA expression of NLRP3 inflammasome related genes and secretion of downstream cytokines. In conclusion, NF-κB-94 ins/del ATTG and CARD8 (rs2043211) genotypes might serve as novel biomarkers and potential targets for ALL.

Keywords: NLRP3, polymorphism, NF-κB, CARD8, acute lymphoblastic leukemia

INTRODUCTION

Acute lymphoblastic leukemia (ALL) is a clonal disorder driven by accumulation of progenitor cells in the peripheral blood and bone marrow (1, 2). Although adult ALL accounts for only 20% of leukemia, it is more common in childhood acute leukemia (80% of cases). Nowadays, through traditional chemotherapy, the cure rate of ALL can only reach about 20–40% in adults compared to 80% in children (3, 4). Adult patients present higher risk features at diagnosis, more likely to come up with chemotherapy resistance and higher relapse rate after complete remission (CR) (5). Multiple studies reported that the genetic variants of some metabolism and inflammation related genes contribute to ALL pathogenesis and prognosis (6, 7).
Inflammasomes are large cytosolic multiprotein complexes that assemble in response to infection or stress-associated stimuli and lead to the activation of caspase-1-mediated innate immune responses (8). The NOD-like receptor family was the first family of sensor proteins discovered to form inflammasomes. Among the inflammasomes, the NLRP3 inflammasome has been the most thoroughly studied. NLRP3 inflammasome is composed of NLRP3, the adaptor protein ASC (apoptosis-associated speck-like protein containing a CARD) and caspase-1 (9). NLRP3 inflammasome can be activated by exogenous pathogen invasion or in vivo cell damage and death, and then lead to the interaction of the PYD domain in NLRP3 and ASC proteins. Assembled inflammasome triggers the cleavage of dormant procaspase-1 into its active form, which turns the inactive proinflammatory cytokines pro-IL-1β and pro-IL-18 into mature and biologically active IL-1β and IL-18, respectively (10, 11). Caspase recruitment domain-containing protein (CARD) 8 interacts with cleaved caspase-1 and then triggers downstream inflammatory response through nuclear factor (NF)-κB pathway (12). NLRP3 inflammasome could modulate cellular levels of the glucocorticoid receptor and affect glucocorticoid resistance of ALL patients (13). However, it is still unknown whether and how NLRP3 inflammasome contributes to the pathogenesis and clinical features of ALL.

Nowadays, the advanced high-throughput techniques have boosted the discovery of genetic variations including copy number variants (CNVs), indels (deletions or insertions), structural variants and single nucleotide polymorphisms (SNPs) (14). SNPs of NLRP3 greatly influence pathogenic challenges and lead to disease outcome, such as autoimmune diseases (15), cardiovascular diseases (16), and malignant tumors (17). The SNP of CARD8 rs2043211 polymorphism has been confirmed to be associated with cardiovascular diseases according to a meta-analysis (18). Accumulating evidences have revealed that NF-κB-94 ins/del ATTG polymorphism is associated with cancer risk such as gastric cancer, hepatocellular carcinoma, and lung cancer (19–21). The polymorphism rs1946518 of NLRP3 effector molecule IL-18 has been shown to influence periodontitis (22) and hepatocellular carcinoma (23). The SNP rs16944 of the other NLRP3 effector molecule IL-1β has been reported contributing to cervical carcinoma (24) and gastritis risk (25). Thus, polymorphism of NLRP3 inflammasome related genes showed strong relevance with malignant tumors, but the regulatory role of the SNP of NLRP3 inflammasome related genes in the ALL bone marrow microenvironment has not been reported until now.

Therefore, to determine the susceptibility and clinical significance of the NLRP3 inflammasome in ALL, we examined the SNPs of four NLRP3 inflammasome related genes, including NF-κB-94ins/del ATTG, CARD8 (rs2043211), IL-18 (rs1946518), and IL-1β (rs16944). We are looking forward to provide evidences for clinical management of ALL.

### MATERIALS AND METHODS

#### Study Subjects and Sample Collection

A total of 308 ALL patients and 300 sex- and age-matched healthy controls were included in this study. The diagnosis of enrolled ALL was based on NCCN Guidelines for acute lymphoblastic leukemia (ALL) (26). The demographic and clinical characteristics of these subjects were shown in Table 1. The protocol was approved by the Medical Ethics Committee of Qilu Hospital of Shandong University. Informed consents were obtained from the participants.

For determination of polymorphisms, we collected anti-coagulated bone marrow or peripheral blood from ALL patients or peripheral blood from healthy controls. For testing the association of NLRP3 molecules mRNA expression or plasma levels with the genetic polymorphisms, we used bone marrow samples from newly-diagnosed ALL patients. Bone marrow or peripheral blood samples were centrifuged at 430 g for 5 min, and the plasma supernatants were frozen at −80°C for the determination of cytokines by ELISA. The mononuclear cells were isolated by Ficoll-Hypaque density gradient centrifugation, and re-suspended in sterile PBS and centrifuged again for 5 min at 430 g to remove remaining Ficoll solution. The mononuclear cells were stored −20°C for DNA and RNA extraction.

#### DNA Extraction and Genotyping

DNA was extracted using TIANamp Genomic DNA Kit (Tiangen, Beijing, China) according to the supplier’s recommendations. The concentration and purity of DNA were accessed at 260/280 absorbance using NanoDrop spectrophotometer. The genotype of CARD8 (rs2043211), IL-18 (rs1946518), or IL-1β (rs16944) was performed using TaqMan® allelic discrimination assay (Cat# 4351379; Thermo Fisher Scientific, USA) in accordance with the manufacturer’s instruction. Followed the standard protocol, 3 μl TaqMan Universal PCR Master Mix (2×), 0.15 μl pre-designed primers and probes (40×), 1 μl (100 ng/μl) of DNA and 1.85 μl ddH2O make up the 6 μl volume reaction system. The NF-κB-94 ins/del ATTG polymorphism was examined by using the forward primer: 5’-CCG TGC TGC CTG GTT-3’, reverse primer: 5’-GCT GGA GCC GAT AGA-3’, and probe 1: 5’-VIC-ACC ATT GAT TGG GCC -MGB-3’ and probe 2: 5’-FAM-CGA CCA TTG GGC C-MGB-3’. A total 10 μl volume reaction system was composed of 5 μl TaqMan Universal PCR Master Mix (2×), 0.8 μl (10 μM) forward primer, 0.8 μl (10 μM) reverse primer.

#### Table 1 | The demographic and clinical characteristics of ALL patients and controls.

|                          | ALL patients | Controls     |
|--------------------------|--------------|--------------|
| No.                      | 308          | 300          |
| Age, mean ± SD           | 38.76 ± 17.02| 40.06 ± 12.98|
| Gender (M/F)             | 184/124      | 167/133      |
| WBC count (<30*10^9/L)   | 240/68       | NA           |
| Hb (<60 g/L)             | 250/58       | NA           |
| Cr (<115 g/L)            | 298/10       | NA           |
| Spleen (Splenomegaly/Non-Splenomegaly) | 248/60 | NA |
| AST (<125 g/L)           | 291/17       | NA           |
| Fasting blood-glucose (normal/abnormal)| 242/66 | NA |
| Immunophenotype (T/B)    | 66/242       | NA           |
| Ph(PH+) (Ph–)            | 235/73       | NA           |
TABLE 2 | The primer sequences of real-time quantitative PCR.

| Gene       | Forward (5′-3′) | Reverse (5′-3′) |
|------------|-----------------|-----------------|
| NF-κB      | TCC AGA ACA ACA ACC CC | GAT CTT GAG CTC GGC AGT GT |
| NLRP3      | CAG ACT TCT GTC TGT GGG ACT GA | TCC TGA CAA CAT GCT GAT GTG A |
| IL-1β      | GCC GTA ACA AGA TGA AGT GCT C | GAA CCA GCA TCT TCC TCA G |
| IL-18      | GCT TGA ATC TAA ATT ATC AGT C | GAA GAT TCA AAT TGC ATT TTA T |
| Caspase-1  | AAA TCT CAC TGG TTC GGA CAT G | GCA ACT TGC TGT CAG AGG GCT T |
| ASC        | TGG ATG CTC TGT ACG GGA AG | CCA GGC TGG TGT GAA ACT GAA |
| GAPDH      | GCT TGC TGC TCC TGC TGG TC | GGT GAC TGC GAC CTG CAC CT |

TABLE 3 | The association between selected SNPs and susceptibility of ALL.

| SNP              | Model/Allele | Genotype/Allele | Controls | ALL patients | P value |
|------------------|--------------|-----------------|----------|--------------|---------|
|                 |              |                | Count   | %            | Count   | %            |         |
| NF-κB 94ins/delATTG  | Allele       |                | W       | 339          | 56.5    | 383          | 62.2    | 0.047   |
|                 |              |                | D       | 261          | 43.5    | 233          | 37.8    |         |
|                 | Codominant   |                | WW      | 98           | 32.7    | 119          | 38.6    |         |
|                 |              |                | WD      | 143          | 47.7    | 145          | 47.1    |         |
|                 |              |                | DD      | 59           | 19.6    | 44           | 14.3    |         |
| CARD8 8rs2043211 | Dominant     |                | AA      | 93           | 31      | 62           | 20.1    | 0.027   |
|                 |              |                | AT+TT   | 207          | 69      | 246          | 79.9    |         |
|                 | Codominant   |                | AA      | 93           | 31      | 62           | 20.1    |         |
|                 |              |                | AT      | 134          | 44.7    | 172          | 55.8    |         |
|                 |              |                | TT      | 73           | 24.3    | 74           | 24      |         |

primer, 0.2 µl (10 µM) probe 1, 0.2 µl (10 µM) probe 2, 2.0 µl ddH2O and 1 µl (100 ng/µl) of DNA. ABI7500 Real-Time PCR system (Applied Biosystems, Foster City, CA, USA) was applied for TaqMan SNP genotyping assay, conditions as followed: 50°C for 2 min, 95°C for 10 min, and then 40 cycles of amplification (92°C denaturation for 15 s, 62°C annealing/extension for 60 s). ABI7500 software v 1.3 and TaqMan Genotyper software were used to analyze the genotyping.

Real-Time Quantitative PCR Detection for NF-κB, NLRP3, IL-1β, IL-18, Caspase-1, and ASC

We determined the mRNA expression of NF-κB, NLRP3, IL-1β, IL-18, Caspase-1, and ASC by real-time quantitative PCR. RNA was extracted using TRizol reagent (Invitrogen Life Technologies, Carlsbad, CA). A total of 1 µg RNA was used for reverse transcription of total 10 µl volume by applying the PrimeScript RT reagent Kit Perfect Real Time (Takara Bio, Japan). The quantitative PCR was performed on the LightCycler 480II real-time PCR system (Roche, Switzerland) according to standard protocol. The primers were shown in Table 2. The quantitative PCR is a 10 µl volume, comprised of 5 µl of 2x SYBR Green Real-time PCR Master Mix, 1 µl of cDNA, 0.8 µl of the forward and reverse primers, and 3.2 µl ddH2O. The results were expressed relative to the number of GAPDH transcripts used as an internal control.

ELISA for IL-18 and IL-1β

The levels of IL-18 and IL-1β in plasma were determined with a quantitative sandwich enzyme-linked immunosorbent assay (ELISA) in accordance with the manufacturer’s recommendations (lower detection limits were 62.5 pg/ml for IL-18 and 3.9 pg/ml for IL-1β; IL-18 ELISA kit was bought from Abcam and IL-1β ELISA kit was bought from R&D systems, USA).

Statistical Analysis

The p value of the Hardy–Weinberg equilibrium (HWE) was calculated using the calculator available at the Helmholtz Center Munich website. In addition to allelic frequencies, we analyzed genotypic frequencies under three genetic models, specifically, the codominant, dominant, and recessive models. Association between the SNPs and ALL susceptibility was calculated by a chi-squared (χ2) test or a Fisher’s exact test. Univariate logistic regression analysis was used to analyze p values and odds ratios (ORs) with a corresponding 95% confidence interval (95% CI). A two-tailed p < 0.05 was considered statistically significant. All statistical analysis was performed using SPSS 22.0 software (SPSS Inc., Chicago, IL, USA).

RESULTS

The Polymorphisms of NF-κB-94 ins/del ATTG and CARD8 (rs2043211) Contribute to the Susceptibility of All

We examined SNPs of NLRP3 inflammasome related genes: NF-κB (-94 ins/del ATTG), CARD8 (rs2043211), IL-18 (rs1946518), and IL-1β (rs16944) in 308 ALL patients and 300 healthy controls. The distribution of AT/TT genotype under dominant and TT genotype under codominant models for rs2043211 in CARD8...
were found significantly different between ALL patients and controls. In addition, both the D allele in allelic frequencies and DD genotype under the codominant model of NF-κβ−94 ins/del ATTG were significantly associated with the susceptibility to ALL ($p < 0.05$; **Table 3**).

Univariate logistic regression analysis was used for analyzing NF-κβ and CARD8. For 94 ins/del ATTG in NF-κβ, the frequency of D allele was lower in ALL patients compared to controls (37.8 vs. 43.5%), and it was significantly associated with ALL susceptibility ($OR = 0.790, 95\% CI 0.628–0.994, p = 0.044$). Furthermore, the frequency of the DD genotype of NF-κβ (14.3 vs. 19.6%) was obviously lower in ALL rather than homozygote insertion or wildtype (WW) genotype under codominant model, which hinted a significant association with ALL susceptibility ($OR = 0.641, 95\% CI 0.383–0.946, p = 0.043$). For CARD8 under dominant model, the AT/TT genotype was significantly higher in ALL patients compared to controls (79.9 vs. 69.0%), and was associated with ALL susceptibility ($OR = 1.783, 95\% CI 1.230–2.583, p = 0.002$). As for codominant model, both AT and TT genotypes of CARD8 (55.8 vs. 44.7%; 24.0 vs. 24.3%, respectively) were much higher in ALL compared to controls, and it significantly contributed to ALL susceptibility rather than AA genotype ($OR = 1.925, 95\% CI 1.300–2.583, p = 0.001; OR = 1.521, 95\% CI 0.964–2.399, p = 0.072$, respectively; **Table 4**). Interestingly, the distribution of CARD8 rs2043211 and NF-κβ-94 ins/del ATTG was found different between ALL patients and controls. NF-κβ polymorphism demonstrated a protective effect, while AT/TT genotype of CARD8 (rs2043211) greatly increased the ALL susceptibility.

### TABLE 4 | NF-κβ-94 ins/del ATTG and CARD8 (rs2043211) contribute to susceptibility of ALL.

| SNP Model/Allele | Genotype/Allele | Controls | ALL patients | OR (95%CI) | P value |
|------------------|-----------------|----------|--------------|------------|---------|
| **Allele**       | **W**           | 339      | 383          | 62.2       | 1.000   |
|                  | **D**           | 261      | 233          | 37.8       | 0.790 (0.628–0.994) | 0.044 |
| **Codominant**   | **WW**          | 98       | 119          | 38.6       | 1.000   |
|                  | **WD**          | 143      | 145          | 47.1       | 0.835 (0.568–1.189) | 0.317 |
|                  | **DD**          | 59       | 44           | 14.3       | 0.614 (0.383–0.986) | 0.043 |
| **CARD8rs2043211** | **Dominant** | **AA** | 93 | 62 | 20.1 | 1.000 |
|                  | **AT+TT** | 207 | 246 | 79.9 | 1.783 (1.230–2.583) | 0.002 |
| **Codominant**   | **AA**          | 93       | 62           | 20.1       | 1.000   |
|                  | **AT**          | 134      | 172          | 55.8       | 1.925 (1.300–2.852) | 0.001 |
|                  | **TT**          | 73       | 74           | 24         | 1.521 (0.964–2.399) | 0.072 |

### TABLE 5 | The polymorphisms of NF-κβ-94 ins/del ATTG and CARD8 (rs2043211) were associated with prognosis characteristics of ALL.

| SNP Model/Allele | Genotype/Allele | Clinical characteristic | OR (CI95%) | P value |
|------------------|-----------------|-------------------------|------------|---------|
| **Recessive**    | **WBC Count<30**| **>30** | 192 | 80 | 64 | 94.1 | 1.000 |
|                  | **DD**          | 48 | 20 | 4 | 5.9 | 0.250 (0.087–0.721) | 0.010 |
| **Codominant**   | **WBC Count<30**| **>30** | 91 | 37.9 | 28 | 41.2 | 1.000 |
|                  | **WD**          | 109 | 45.4 | 36 | 52.9 | 1.073 (0.609–1.892) | 0.807 |
|                  | **DD**          | 40 | 16.7 | 4 | 5.9 | 0.325 (0.107–0.996) | 0.048 |
| **CARD8 rs2043211** | **Dominant** | **IPT (B-cell)** | **IPT (T-cell)** | 55 | 22.7 | 7 | 10.6 | 1.000 |
|                  | **AT+TT** | 187 | 77.3 | 59 | 89.4 | 2.479 (1.071–5.738) | 0.034 |
| **Codominant**   | **IPT (B-cell)** | **IPT (T-cell)** | 55 | 22.7 | 7 | 10.6 | 1.000 |
|                  | **AT**          | 127 | 52.5 | 45 | 68.2 | 2.748 (1.182–6.559) | 0.019 |
|                  | **TT**          | 60 | 24.8 | 14 | 21.2 | 1.833 (0.688–4.876) | 0.225 |
the correlation between NLRP3 genetic polymorphisms and prognosis of ALL.

We found that NF-κB-94 ins/del ATTG was significantly associated with the lower white blood cells (WBC) count, which is supposed to be a poor prognostic indicator as long as WBC count over $30 \times 10^9 / L$. After univariate logistic regression analysis, compared with WD/WW genotype of NF-κB under recessive model, DD genotype significantly associated with a lower WBC count (20.0 vs. 5.9%; OR = 0.250, 95% CI 0.087–0.721, $p = 0.010$). Under codominant model, DD genotype also associated with a lower WBC count compared to WW genotype (16.7 vs. 5.9%; OR = 0.325, 95% CI 0.403–0.998, $p = 0.048$). NF-κB-94 ins/del ATTG under both recessive and codominant model, patients with DD genotype tend to have a lower WBC count (Table 5).

Furthermore, CARD8 (rs2043211) was also found to be correlated with immunophenotype of ALL, which primary divided into T-cell immunophenotype and B-cell immunophenotype. According to NCCN Guideline for ALL, immunophenotype is a strong prognostic indicator. Compared with AA genotype under dominant model, AT/TT genotype was associated with T-cell immunophenotype (77.3 vs. 89.4%; OR = 2.479, 95% CI 1.071–5.738, $p = 0.034$). Under codominant model, AT genotype was also associated with T-cell immunophenotype compared to AA genotype (52.5 vs. 68.2%; OR = 2.748, 95% CI 1.182–6.559, $p = 0.019$; Table 5). Thus, DD genotype of NF-κB-94 ins/del ATTG was showed as a protective factor, while AT/TT genotype of CARD8 (rs2043211) associated with a poor prognosis.

### Table 6: The association between selected SNPs and clinical characteristics of ALL patients.

| SNP          | Model/Allele Genotype/Allele | Clinical characteristics | OR (CI95%) | P value |
|--------------|-----------------------------|-------------------------|------------|---------|
| **NF-κB Recessive** | WW + WD | Hb < 60 | 213 | 85.2 | 1.000 |
| 94ins/delATTG | WW | Hb > 60 | 43 | 74.1 | 1.000 |
|            | WD | Hb < 60 | 15 | 25.9 | 0.698 (0.300–1.668) | 0.415 |
|            | WD | Hb > 60 | 213 | 85.2 | 1.000 |
|            | DD | Hb < 60 | 15 | 25.9 | 0.498 (0.251–0.986) | 0.046 |
|            | DD | Hb > 60 | 37 | 14.8 | 1.000 |
| **Codominant** | WW | Splenomegaly | 99 | 39.9 | 1.000 |
|              | WD | Non-Splenomegaly | 120 | 48.4 | 1.031 (0.541–1.966) | 0.926 |
|              | DD | Splenomegaly | 29 | 11.7 | 2.080 (1.165–5.625) | 0.019 |
| **Allele** | WW | Splenomegaly | 318 | 64.1 | 1.000 |
|              | WD | Non-Splenomegaly | 65 | 35.9 | 1.000 |
|              | DD | Splenomegaly | 178 | 35.9 | 1.512 (1.010–2.262) | 0.045 |
| **IL-18 Recessive** | GT + GG | AST < 125 | 223 | 76.6 | 1.000 |
| rs1946518   | GT | 125 | 38 | 63.3 | 1.000 |
|            | TT | AST < 125 | 54 | 21.8 | 2.080 (1.135–3.811) | 0.018 |
|            | TT | 125 | 22 | 36.7 | 1.000 |
| **Codominant** | GG | Glu < 6.1 | 59 | 24.4 | 1.000 |
|              | GT | > 6.1 | 121 | 50.0 | 0.754 (0.405–1.401) | 0.371 |
|              | TT | < 6.1 | 62 | 25.6 | 0.433 (0.189–0.990) | 0.047 |
| **Allele** | GG | Glu < 6.1 | 239 | 49.4 | 1.000 |
|              | GT | > 6.1 | 245 | 50.6 | 0.675 (0.457–0.998) | 0.049 |
|              | TT | < 6.1 | 54 | 40.9 | 1.000 |
| **IL-1β Recessive** | GT + GG | Cr < 115 | 219 | 73.5 | 1.000 |
| rs16944     | GT | > 115 | 40 | 26.5 | 1.000 |
|            | TT | Cr < 115 | 79 | 26.5 | 4.158 (1.143–15.122) | 0.031 |
| **Allele** | GT | > 115 | 15 | 25 | 1.000 |
|              | TT | Cr < 115 | 75 | 49.3 | 3.082 (1.106–8.587) | 0.031 |
statistically associated with hemoglobin (Hb) compared to WW/WD genotype under recessive model. Under codominant model, DD genotype ($p = 0.019$) was significantly associated with splenomegaly in contrast to WW genotype. As for the frequency of allele, compared with the 94insATTG (W) allele, the minor allele homozygotes were also associated with splenomegaly ($p = 0.045$; Table 6).

Under recessive model, TT genotype of IL-18 (rs1946518) was statistically correlated with both splenomegaly and AST concentration in serum compared to GG/GT genotype ($p = 0.018$, $p = 0.034$, respectively). In addition, TT genotype was also found to be related to the fasting blood-glucose under codominant model compared to GG genotype ($p = 0.047$). As for the frequency of allele, compared with the G allele, the T allele homozygote was also associated with the fasting blood-glucose ($p = 0.049$; Table 6).

Furthermore, the polymorphism in IL-1β rs16944 was supposed to have connection with creatinine concentration. Under recessive model, TT genotype ($p = 0.031$) was significantly associated with creatinine concentration by the contrast to GG/GT genotype. As for the frequency of allele, the G allele was also associated with creatinine concentration ($p = 0.031$; Table 6).

Association Between the Polymorphisms and the Expression of NLRP3 Inflammasome Related Genes

The pathogenesis and development of ALL involves a dysregulated immune microenvironment, which contains the production of multiple immunological effector proteins and the activation of the downstream pathways. To further comprehend the relationship between NLRP3 inflammasome related gene polymorphisms and its effective proteins, we use RT-PCR to examine NLRP3 inflammasome related gene expression at mRNA level, and ELISA to detect the secretion of effective proteins.

As for CARD8 (rs2043211), AT genotype showed a significant association with the higher mRNA expression levels of NLRP3 and ASC compared to AA genotype ($p = 0.017$, $p = 0.024$, respectively; Figures 1A,B). We also found that TT genotype was correlated with higher caspase-1 mRNA level when compared to both AA and AT genotype ($p = 0.009$, $p = 0.039$, respectively; Figure 1C). Moreover, TT genotype in CARD8 polymorphism was also found to be associated with IL-18 concentration in ALL bone marrow microenvironment compared to AA genotype (Figure 1D).

As for IL-1β (rs16944) polymorphism, GT genotype was significantly associated with IL-18 expression compared with
GG and TT genotype (\( p = 0.021, p = 0.000 \), respectively; **Figure 2A**), and was also associated with ASC expression compared with TT genotype (\( p = 0.045; \) **Figure 2B**). Our data showed that TT genotype was correlated with IL-1β concentration (\( p = 0.044; \) **Figure 2C**). With the similar trend, TT genotype in IL-1β (rs1946518) polymorphism was also associated with both IL-1β and IL-18 concentration compared to GG genotype (\( p = 0.029, p = 0.022 \), respectively; **Figures 2D,E**). However, GT genotype in IL-18 polymorphism was related to a higher level of NLRP3 and ASC (\( p = 0.034, p = 0.048 \), respectively; **Figures 2F,G**). Besides, we also found significant correlation between concentration of IL-1β in bone marrow and mRNA expression level of IL-1β and ASC (\( p = 0.020, p = 0.001 \), respectively; **Figures 2H,I**). Thus, AT and TT genotype of CARD8 (rs2043211), GT and TT genotype of IL-1β (rs16944) and TT genotype of IL-18 (rs1946518) were associated with higher mRNA expression of NLRP3 related genes and secreted cytokines.

**DISCUSSION**

ALL is a malignant blood disease with origins from somatic genetic alterations in bone marrow microenvironment (27). Though traditional chemotherapy has made a great progress...
in the last decade, ALL patients still have a poor prognosis. Compared with 90% 5-year overall survival in children, it is merely 30–40% in adult ALL. NLRP3 inflammasome systemically exists in human organism, and its activation has been identified as initiation of numerous diseases, such as immune diseases (28), cardiovascular diseases (29), gut homeostasis (30), and even malignant cancers (31). In hematological diseases, genetic polymorphisms of the NLRP3 have been reported to contribute to the pathogenesis of multiple myeloma (32) and lymphoma (33). But what is the correlation between NLRP3 inflammasome and ALL is still unknown. Therefore, our study mainly focused on the relationship between NLRP3 inflammasome and ALL in order to depict the internal communication between them.

We found that the DD genotype and D allele in NF-κB-94 ins/del ATTG was associated with a decreased risk of ALL, and had been considered as a protective factor. With the similar trend, under both recessive mode and codominant model, DD genotype exhibits as a protective factor on WBC count and Hb concentration. NF-κB-94 ins/del ATTG is considered as a protective factor for ALL patients. NF-κB is not only the downstream of NLRP3 inflammasome, but also is involved in many immune and inflammatory responses. In the resting state, NF-κB was found in cytoplasm, combined with several regulatory proteins, which inhibit its function (34, 35). After stimulating factors activate inflammatory responses, it moves into nucleus and binds to specific DNA sequences to modulate apoptosis and proliferation related genes (36). As NF-κB-94 ins/del ATTG polymorphism was determined as a protective factor in our study, this gene polymorphism may result in low affinity to nucleus; however, further studies need to be performed to illuminate its mechanisms.

On the contrary, CARD8 (rs2043211), another polymorphism we focused on, seems to increase the risk for ALL according to our study. It should be noted that TT genotype under codominant model increased the susceptibility of ALL, showed strong positive correlation with caspase-1 mRNA expression and the concentration of IL-18 in bone marrow microenvironment. CARD8 polymorphism was supposed to positively enhanced the NLRP3 inflammasome activation and the susceptibility of ALL.

Since we are aimed to provide new horizons for clinical management of ALL patients, we focused on several clinical indicators that may be related to prognosis. Though there were still many indicators we studied not listed in NCCN Guideline of prognostic indicators, they are significantly related to complications or the survival quality of ALL patients. According to our study, polymorphisms of IL-1β and IL-1β should be significantly associated with blood routine index, biochemical criterion.

In conclusion, our investigation found that NLRP3 inflammasome-related SNPs, especially NF-κB-94 ins/del ATTG and CARD8 (rs2043211) genotype might serve as a novel biomarker and potential targets for ALL. Furthermore, IL-1β (rs16944) and IL-18 (rs1946518) polymorphism are able to predict the prognosis and guide the treatment of ALL. Further research with a larger sample size and in-depth mechanism study is required to validate the clinical potential of IL-1β (rs16944) and IL-18 (rs1946518) polymorphism.

**ETHICS STATEMENT**

This study was carried out in accordance with the recommendations of CIOMS Guideline. The protocol was approved by the Laboratory Animal Ethic Committee of Qilu Hospital of Shandong University.

**AUTHOR CONTRIBUTIONS**

DM and CJ conceived and designed the experiments. CZha performed the experiments. RW and FH analyzed the data. YS, CZho, and MH contributed reagents, materials, and analysis tools. XH and XZ wrote the paper. All authors read the manuscript critically and approved the submitted version.

**FUNDING**

This work was supported by grants from National Natural Science Foundation of China (No. 91642110, 81873439, 81470319), Shandong Key Research and Development Program (2017GSF218050), the Fundamental Research Funds of Shandong University (2018JC018), and grants from Taishan Scholars Program.

**REFERENCES**

1. Stock W, Johnson JL, Stone RM, Kolitz JE, Powell BL, Wetzler M, et al. Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia. *Cancer.* (2013) 119:90–8. doi: 10.1002/cncr.27617
2. Thomas DA, O’Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. *J Clin Oncol.* (2010) 28:3880–9. doi: 10.1200/JCO.2009.26.9456
3. Kantarjian H, Thomas D, O’Brien S, Cortes J, Giles F, Jeha S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. *Cancer-Am Cancer Soc.* (2004) 101:2788–801. doi: 10.1002/cncr.20668
4. Sive JI, Buck G, Fielding A, Lazarus HM, Litow M, Lugner S, et al. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. *Br J Haematol.* (2012) 157:463–71. doi: 10.1111/j.1365-2141.2012.09095.x
5. Hoelzer D, Walewski J, Dohner H, Viardot A, Hiddemann W, Spiekermann K, et al. Improved outcome of adult Burkitt lymphoma leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. *Blood.* (2014) 124:3870–9. doi: 10.1182/blood-2014-03-563627
6. Milosevic G, Kotur N, Krsotinski N, Lazic J, Zukić B, Stankovic B, et al. Variants in TPMT, ITPA, ABCB4 and ABCB1 genes as predictors of 6-mercaptopurine induced toxicity in children with acute lymphoblastic leukemia. *J Med Biochem.* (2018) 37:320–7. doi: 10.1515/jomb-2017-0060
Zhang et al. NLRP3 Polymorphisms Associated With ALL

7. Zehra A, Zehra S, Ismail M, Azhar A. Glutathione S-Transferase M1 and T1 gene deletions and susceptibility to acute lymphoblastic leukemia (all) in adults. Pak J Med Sci. (2018) 34:666–70. doi: 10.12699/pjms.343.14911
8. Franchi L, Munoz-Planillo R, Nunez G. Sensing and reacting to microbes through the inflammasomes. Nat Immunol. (2012) 13:325–32. doi: 10.1038/ni.2231
9. Lamkanfi M, Dixit VM. The inflammasomes. PLoS Pathog. (2009) 5:e1000510. doi: 10.1371/journal.ppat.1000510
10. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. (2002) 10:417–26. doi: 10.1016/S1097-2765(02)00599-3
11. Wang L, Manji GA, Grenier JM, Al-Garawi A, Merriam S, Lora JM, et al. PYPAF7, a novel PYRIN-containing Apaf1-like protein that regulates activation of NF-kappa B and caspase-1-dependent cytokine processing. J Biol Chem. (2002) 277:29874–80. doi: 10.1074/jbc.M203915200
12. Strowig T, Henao-Mejia J, Elinav E, Flavell R. Inflammasomes in health and disease. Nature. (2012) 481:278–86. doi: 10.1038/nature10759
13. Paugh SW, Bonten EMJ, Savig V, Ramsey LB, Thieferfeld WE, Gurung P, et al. NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. Nat Genet. (2015) 47:607–14. doi: 10.1038/ng.3283
14. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nat Genet. (2001) 30:409–60. doi: 10.1038/3507062
15. Villani AC, Lemire M, Fortin G, Louis E, Silverberg MS, Collette C, et al. Single-nucleotide polymorphisms: a perspective of cardiovascular preventive. Rev Assoc Med Bras. (2015) 61:458–68. doi: 10.1590/1806-9282.61.5.458
16. Howell WM, Rose-Zerilli MJ. Cytokine gene polymorphisms, cancer susceptibility, and prognosis. J Natr. (2007) 137:1945–95. doi: 10.1093/jn/137.1.1945
17. Huang H, Bi Q, Wei H, Luo B, He Y. Association between caspase recruitment domain-containing protein 8 rs2043211 polymorphism and cardiovascular disease susceptibility: a systematic review and meta-analysis. Anatol J Cardiol. (2018) 20:70–76. doi: 10.14744/AnatolJCardiol.2018.32650
18. Ungerback J, Belenki D, Jawad UA, Fredrikson M, Fransen K, Elander N, et al. Genetic variation and alterations of genes involved in NFKBappa1/TNFAIP3- and NLRP3-inflammasome signaling affect susceptibility and outcome of colorectal cancer. Carcinogenesis. (2012) 33:2126–34. doi: 10.1093/carcin/bgs256
19. Cheng CW, Su JU, Lin CW, Su CW, Shih CH, Yang SF, et al. Effects of NFKB1 and NFKBIA gene polymorphisms on hepatocellular carcinoma susceptibility and clinicopathological features. PLoS ONE. (2013) 8:e56130. doi: 10.1371/journal.pone.0056130
20. Oltulu YM, Coskunpinar E, Ozkan G, Aynaci E, Yildiz P, Isbir T, et al. Investigation of NF-kappaB1 and NF-kappaB1A gene polymorphism in non-small cell lung cancer. Biomed Res Int. (2014) 2014:350381. doi: 10.1155/2014/530381
21. Tanaka K, Miyake Y, Hanioka T, Furukawa S, Miyatake N, Arakawa M. The IL18 promoter polymorphism, rs1946518, is associated with the risk of periodontitis in Japanese women: the kyushu okinawa maternal and child health study. Tohoku J Exp Med. (2017) 243:159–64. doi: 10.1620/tjem.243.159
22. Zhu SL, Zhao Y, Hu XY, Luo T, Chen ZS, Zhang Y, et al. Genetic polymorphisms—137 (rs187238) and—607 (rs1946518) in the interleukin-18 promoter may not be associated with development of hepatocellular carcinoma. Sci Rep. (2016) 6:39404. doi: 10.1038/srep39404
23. Sun X, Cai H, Li Z, Li S, Yin W, Dong G, et al. Association between IL-1β polymorphisms and gastritis risk: a meta-analysis. Medicine. (2017) 96:e6001. doi: 10.1097/MD.0000000000006001
24. Dutta S, Chakraborty C, Mandal RK, Basu P, Biswas J, Roychoudhury S, et al. Persistent HPV16/18 infection in Indian women with the A-allele (rs6457617) of HL-A-DQB1 and T-allele (rs16944) of IL-1beta—511 is associated with development of cervical carcinoma. Cancer Immunol Immunother. (2015) 64:843–51. doi: 10.1007/s00262-015-1693-5
25. Brown PA, Shah B, Pathi A, Wieduwilt M, Advani A, Aoun P, et al. NCCN guidelines insights: acute lymphoblastic leukemia. Version 1.2017. J Natl Compr Canc Netw. (2017) 15:1091–102. doi: 10.6004/jnccn.2017.0147
26. Huang SF, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. (2015) 373:1541–52. doi: 10.1056/NEJMra1400972
27. Zhong Z, Sanchez-Lopez E, Karin M. Autophagy, NLRP3 inflammasome and auto-inflammatory/immune diseases. Clin Exp Rheumatol. (2016) 34:12–16
28. Liu D, Zeng X, Li X, Mehta JL, Wang X. Role of NLRP3 inflammasome in the pathogenesis of cardiovascular diseases. Basic Res Cardiol. (2017) 113:5. doi: 10.1007/s00395-017-0663-9
29. Zambetti LP, Mortellaro A. NLRPs, microbiota, and gut homeostasis: unravelling the connection. J Pathol. (2014) 233:321–30. doi: 10.1002/path.4357
30. Karki R, Man SM, Kanneganti TD. Inflammasomes and Cancer. Cancer Immunol Res. (2017) 5:94–9. doi: 10.1158/2326-6066.CIR-16-0269
31. Zhao X, Hua M, Yan S, Yu J, Han F, Zhong C, et al. The genetic polymorphisms of NLRP3 inflammasome associated with t helper cells in patients with multiple myeloma. J Immunol Res. (2018) 2018:7569809. doi: 10.1155/2018/7569809
32. Zhao X, Zhang C, Han M, Wang R, Zhong C, Yu J, et al. NLRP3 inflammasome activation plays a carcinogenic role through effector cytokine IL-18 in lymphoma. Oncotarget. (2017) 8:108571–83. doi: 10.18632/oncotarget.21010
33. DiDonato J, Mercurio F, Rosette C, Wu-Li J, Suyang H, Ghosh S, et al. Mapping of the inducible IkappaB phosphorylation sites that signal its ubiquitination and degradation. Mol Cell Biol. (1995) 16:1295–304. doi: 10.1128/MCB.16.4.1295
34. Chen ZJ, Parent L, Maniatis T. Site-specific phosphorylation of I kappaB alpha by a novel ubiquitination-dependent protein kinase activity. Cell. (1996) 84:853–62. doi: 10.1016/0092-8674(96)01064-8
35. Arenzana-Seisdedos F, Thompson J, Rodriguez MS, Bacherie F, Thomas D, Hay RT. Inducible nuclear expression of newly synthesized I kappa B alpha negatively regulates DNA-binding and transcriptional activities of NF-kappa B. Mol Cell Biol. (1995) 15:2689–96. doi: 10.1128/MCB.15.5.2689

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Zhang, Han, Yu, Hu, Hua, Zhong, Wang, Zhao, Shi, Ji and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.